Taking into account genomic studies highlighting the PI3K/mTOR pathway as a common vulnerability in osteosarcomas [377,378], it may be more successful to target these pathways in combination with neoadjuvant and/or adjuvant chemotherapy in order to prevent resistance rather than trying to manage overt resistance at later stages. Here, MTOR is linked to osteosarcoma.